Contraindications to Zopiclone Use
Absolute Contraindications
Zopiclone (and its S-enantiomer eszopiclone) should not be prescribed to patients with compromised respiratory function, severe hepatic impairment without dose reduction, myasthenia gravis, or a history of complex sleep behaviors such as sleep-driving. 1
Respiratory Compromise
- Patients with compromised respiratory function represent a critical contraindication because sedative-hypnotics can precipitate respiratory depression, even though eszopiclone at 2.5-fold the recommended dose (7 mg) did not show respiratory-depressant effects in healthy volunteers. 1
- The FDA labeling explicitly advises caution in patients with any degree of respiratory compromise, making this a relative contraindication that often becomes absolute in clinical practice. 1
Severe Hepatic Impairment
- Severe hepatic impairment requires mandatory dose reduction to 1 mg because systemic exposure doubles in these patients; prescribing standard doses (2–3 mg) without adjustment is contraindicated. 1
- Mild-to-moderate hepatic impairment does not require dose adjustment, but severe disease fundamentally alters drug clearance. 1
Complex Sleep Behaviors
- Patients with a prior history of complex sleep behaviors—including sleep-driving, preparing food while asleep, making phone calls, or engaging in sexual activity without memory of the event—should not receive zopiclone because recurrence risk is high and potentially dangerous. 1
- These behaviors occur more frequently when zopiclone is combined with alcohol or other CNS depressants, making concomitant use a practical contraindication. 1
Strong Relative Contraindications (High-Risk Populations)
Depression and Suicidal Ideation
- Active depression or suicidal tendencies constitute a strong relative contraindication because sedative-hypnotics are frequently used in intentional overdose; the FDA labeling warns of depression and suicidal thoughts, particularly in patients taking both sedatives and hypnotics. 2, 1
- In Sweden, zopiclone was implicated in 17% of all intoxication suicides during 2012–2020, with women comprising 56% of fatalities; 87% of victims had a valid prescription, indicating that prescribing to high-risk patients directly contributes to suicide deaths. 3
- The least amount of drug feasible should be prescribed at any one time in patients with depressive symptoms, and protective measures must be in place. 1
Substance Use Disorder
- Patients with a history of drug or alcohol abuse are at markedly elevated risk for zopiclone dependence; case reports document severe withdrawal symptoms (palpitations, sweating, hallucinations, seizures) after chronic use, with one patient escalating to 112.5 mg daily over 12 years. 4, 5
- Dependency occurs more commonly in patients with prior substance abuse or psychiatric illness, and zopiclone has documented potential for abuse and addiction similar to benzodiazepines. 5
Alcohol-Related Disease and Biliary Stone
- Patients with alcohol-related disease or biliary stone face a dramatically increased risk of acute pancreatitis when using zopiclone; the adjusted odds ratio for acute pancreatitis is 14.44 (95% CI 7.47–27.89) in active zopiclone users with these comorbidities, compared with never-users without these conditions. 6
- Even without these comorbidities, active zopiclone use carries an adjusted OR of 2.36 (95% CI 1.70–3.28) for acute pancreatitis. 6
Concomitant CNS Depressants
- Concurrent use of alcohol or other CNS-depressant medications is contraindicated because of additive psychomotor impairment and increased risk of complex sleep behaviors. 1
- An additive effect on psychomotor performance was demonstrated when eszopiclone was coadministered with ethanol. 1
Special Population Considerations
Pregnancy and Lactation
- Zopiclone is Pregnancy Category C; animal studies show increased post-implantation loss, decreased postnatal pup weights and survival, and increased pup startle response at all doses tested (lowest dose 60 mg/kg/day, 200 times the maximum recommended human dose). 1
- Use during pregnancy is contraindicated unless the potential benefit clearly justifies the fetal risk. 1
- It is unknown whether zopiclone is excreted in human milk; caution is required when prescribing to nursing mothers, and the drug should generally be avoided. 1
Pediatric Population
- Safety and effectiveness in children below age 18 have not been established, making pediatric use contraindicated. 1
Elderly and Debilitated Patients
- While not an absolute contraindication, elderly patients (≥65 years) and debilitated individuals require a reduced starting dose of 1 mg because of heightened risk for impaired motor and cognitive performance, falls, and unusual sensitivity to sedative-hypnotics. 1
- Observational data link hypnotic use in older adults to increased risk of dementia (hazard ratio 2.34,95% CI 1.92–2.85), fractures, and major injuries. 2, 7
Drug Interactions Requiring Avoidance
Potent CYP3A4 Inhibitors
- Concomitant use with potent CYP3A4 inhibitors (e.g., ketoconazole) requires dose reduction because these agents increase zopiclone systemic exposure; failure to adjust the dose is a relative contraindication. 1
Serotonergic Antidepressants (in Overdose Settings)
- In the context of zopiclone overdose causing methemoglobinemia, methylene blue (the standard antidote) is contraindicated in patients on serotonergic antidepressants because of serotonin syndrome risk; ascorbic acid must be used instead. 8
Guideline-Based Positioning
Not a First-Line Agent
- The American Academy of Sleep Medicine (2017) does not recommend zopiclone as a first-line pharmacologic option for chronic insomnia because it is absent from the guideline's list of preferred hypnotic agents, which favor drugs with stronger evidence of efficacy and safety. 9
- Eszopiclone (the S-enantiomer) receives only a weak recommendation for sleep-onset and sleep-maintenance insomnia due to limited high-quality evidence. 9
Intellectual Disability Population
- In patients with intellectual disability, benzodiazepines and Z-drugs (including zopiclone) show higher rates of paradoxical responses, treatment resistance, and adverse effects, making their use inappropriate in this population. 10
Common Pitfalls to Avoid
- Do not prescribe zopiclone immediately before bedtime if the patient cannot dedicate at least 7–8 hours to sleep, as taking the drug while still active increases risk of short-term memory impairment, hallucinations, impaired coordination, dizziness, and lightheadedness. 1
- Do not prescribe standard doses (2–3 mg) to elderly patients or those with severe hepatic impairment without reducing to 1 mg. 1
- Do not combine zopiclone with alcohol or other sedating medications because of multiplicative safety risks. 1
- Do not prescribe for longer than 4–12 weeks without reassessment, as long-term use increases dependency risk and efficacy data support only short-term treatment. 7, 5
- Do not ignore rebound insomnia after discontinuation; many clinical trials document rebound effects in a minority of patients, and abrupt cessation can precipitate severe withdrawal symptoms including seizures. 5